Navigation Links
Bacterin International Holdings, Inc. Schedules Conference Call to Present Fourth Quarter and Full Year 2010 Financial Results
Date:3/17/2011

BELGRADE, Mont., March 17, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE) ("Bacterin"), announced today that it has scheduled a conference call for Tuesday, March 29, 2011 at 10:00 a.m. (ET) to discuss the Company's financial results for its fourth quarter and full year 2010, which ended December 31, 2010.   Bacterin International Holdings, Inc. intends to issue its earnings release after the market close on Monday, March 28, 2011.Conference Call Details:Date/Time:Tuesday, March 29, 2011—10:00 a.m. (ET)Telephone Number:888-713-4216International Dial-In Number:617-213-4868Participant Pass code:74035725Internet Access:
www.bacterin.com or www.earnings.comIt is recommended that participants phone-in at least 10 minutes before the call is scheduled to begin. Participants may pre-register for the call at  https://www.theconferencingservice.com/prereg/key.process?key=PMQXFMDGD

Pre-registrants will be issued a pin number to use when dialing into the live call which will provide quick access to the conference by bypassing the operator upon connection. A replay of the conference call in its entirety will be available approximately one hour after its completion by dialing 888-286-8010 (U.S.), 617-801-6888 (International) and entering the pass code 98452278 and on the Internet at www.earnings.com.

About Bacterin International Holdings, Inc.Bacterin International Holdings, Inc. ("Bacterin") develops, manufactures and markets biologics products to domestic and international markets.  Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold and promote bone and other tissue growth.  These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain by facet joint stabilization, promotion of bone fusion in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral bone defect repair in articulating joint surgeries.

Bacterin's Medical Device division develops anti-microbial coatings based upon proprietary coating technologies. Bacterin develops, employs, and licenses bioactive coatings for various medical device applications.  Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination.

Headquartered in Belgrade, Montana, Bacterin operates a 32,000 square foot, state-of-the-art, fully compliant and FDA registered facility, equipped with four "Class 100" clean rooms.  For further information please visit www.bacterin.com.

Certain statements in this news release may constitute "forward-looking" statements within the meaning of section 21E of the Securities and Exchange Act of 1934.  The Company believes that its expectations, as expressed in these statements are based on reasonable assumptions regarding the risks and uncertainties inherent in achieving those expectations.  These statements are not, however, guarantees of future performance and actual results may differ materially.  Risk factors are listed in the most recent 8-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission.  


'/>"/>

SOURCE Bacterin International Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin International Completes $3 Million Private Placement
2. Bacterin International Introduces OsteoSelect(R) DBM Putty
3. Bacterin International Secures Three-Year Agreement to Distribute Biologic Products to Broadlanes Network of Over 6,000 Medical Facilities
4. Bacterin International Holdings, Inc. Completes Merger and $7.5 Million Raise
5. Bacterin International Holdings, Inc. to Present at the 6th Annual Fall Growth Stock Conference Hosted by Security Research Associates, Inc.
6. Bacterin International to Present at Singular Research 5th Annual Best of the Uncovereds Conference
7. Bacterin International Holdings, Inc. Schedules Conference Call to Present Third Quarter 2010 Financial Results
8. Bacterin International Holdings, Inc. Reports Third Quarter 2010 Financial Results
9. Bacterin International Holdings to Present at the OneMedForum San Francisco 2011
10. Bacterin International to Announce Launch of OsteoSponge®SC at American Academy of Orthopedic Surgeons 2011 Annual Meeting February 15-19
11. Bacterin International Announces Major Orthopedic Hospital Group to Begin Use of OsteoSponge®SC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology:
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
Breaking Medicine News(10 mins):